
Yanick J Crow

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1058610/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi–GoutiÔres syndrome. Developmental Medicine and Child Neurology, 2022, 64, 266-271.	2.1	12
2	Autosomal dominant ADAR c.3019G>A (p.(G1007R)) variant is an important mimic of hereditary spastic paraplegia and cerebral palsy. Brain and Development, 2022, 44, 153-160.	1.1	3
3	The type I interferonopathies: 10 years on. Nature Reviews Immunology, 2022, 22, 471-483.	22.7	164
4	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.9	31
5	Mutations in RNU7-1 Weaken Secondary RNA Structure, Induce MCP-1 and CXCL10 in CSF, and Result in Aicardi-Goutières Syndrome with Severe End-Organ Involvement. Journal of Clinical Immunology, 2022, 42, 962-974.	3.8	8
6	A partial form of inherited human USP18 deficiency underlies infection and inflammation. Journal of Experimental Medicine, 2022, 219, .	8.5	28
7	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp> / <scp>PRAAS</scp> , <scp>SAVI</scp> , and <scp>AGS</scp> . Arthritis and Rheumatology, 2022, 74, 735-751.	5.6	23
8	Type I interferon–related kidney disorders. Kidney International, 2022, 101, 1142-1159.	5.2	21
9	DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. Journal of Clinical Immunology, 2022, 42, 1310-1320.	3.8	7
10	Delineating the epilepsy phenotype of NRROS-related microgliopathy: A case report and literature review. Seizure: the Journal of the British Epilepsy Association, 2022, 100, 15-20.	2.0	3
11	Cerebral Microangiopathy in Leukoencephalopathy With Cerebral Calcifications and Cysts: A Pathological Description. Journal of Child Neurology, 2021, 36, 133-140.	1.4	3
12	Leukoencephalopathy with calcifications and cysts: Genetic and phenotypic spectrum. American Journal of Medical Genetics, Part A, 2021, 185, 15-25.	1.2	15
13	Rheumatoid factor positive polyarticular juvenile idiopathic arthritis associated with a novel <i>COPA</i> mutation. Rheumatology, 2021, 60, e171-e173.	1.9	6
14	Overview of STING-Associated Vasculopathy with Onset in Infancy (SAVI) Among 21 Patients. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 803-818.e11.	3.8	98
15	Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. Journal of Clinical Immunology, 2021, 41, 603-609.	3.8	16
16	LACC1 deficiency links juvenile arthritis with autophagy and metabolism in macrophages. Journal of Experimental Medicine, 2021, 218, .	8.5	17
17	STING-Mediated Lung Inflammation and Beyond. Journal of Clinical Immunology, 2021, 41, 501-514.	3.8	48
18	Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Science Immunology, 2021, 6, .	11.9	161

#	Article	IF	CITATIONS
19	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. Journal of Experimental Medicine, 2021, 218, .	8.5	185
20	Novel compound heterozygous <i>STN1</i> variants are associated with Coats Plus syndrome. Molecular Genetics & Genomic Medicine, 2021, 9, e1708.	1.2	3
21	Opsoclonusâ€myoclonus in Aicardiâ€Goutià res syndrome. Developmental Medicine and Child Neurology, 2021, 63, 1483-1486.	2.1	4
22	JAK inhibition in the type I interferonopathies. Journal of Allergy and Clinical Immunology, 2021, 148, 991-993.	2.9	19
23	Enhanced cGAS-STING–dependent interferon signaling associated with mutations in ATAD3A. Journal of Experimental Medicine, 2021, 218, .	8.5	43
24	Erythrocyte-derived mitochondria take to the lupus stage. Cell Metabolism, 2021, 33, 1723-1725.	16.2	3
25	Mitochondrial Nucleic Acid as a Driver of Pathogenic Type I Interferon Induction in Mendelian Disease. Frontiers in Immunology, 2021, 12, 729763.	4.8	2
26	Mitochondrial Nucleic Acid as a Driver of Pathogenic Type I Interferon Induction in Mendelian Disease. Frontiers in Immunology, 2021, 12, 729763.	4.8	18
27	Treatments in Aicardi–GoutiÃ [¨] res syndrome. Developmental Medicine and Child Neurology, 2020, 62, 42-47.	2.1	70
28	Circulating Interferonâ€Î± Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. Arthritis and Rheumatology, 2020, 72, 195-197.	5.6	15
29	Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. Rheumatology, 2020, 59, 1171-1174.	1.9	5
30	Use of ruxolitinib in COPA syndrome manifesting as life-threatening alveolar haemorrhage. Thorax, 2020, 75, 92-95.	5.6	36
31	Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurology, The, 2020, 19, 31-33.	10.2	14
32	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. Rheumatology, 2020, 59, 1927-1937.	1.9	26
33	PSMB10, the last immunoproteasome gene missing for PRAAS. Journal of Allergy and Clinical Immunology, 2020, 145, 1015-1017.e6.	2.9	42
34	Genetic and phenotypic spectrum associated with IFIH1 gainâ€ofâ€function. Human Mutation, 2020, 41, 837-849.	2.5	63
35	Analysis of U8 snoRNA Variants in Zebrafish Reveals How Bi-allelic Variants Cause Leukoencephalopathy with Calcifications and Cysts. American Journal of Human Genetics, 2020, 106, 694-706.	6.2	17
36	cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nature Genetics, 2020, 52, 1364-1372.	21.4	105

#	Article	IF	CITATIONS
37	JAK Inhibition in the Aicardi–Goutières Syndrome. New England Journal of Medicine, 2020, 383, 2190-2193.	27.0	24
38	Adult-Onset ANCA-Associated Vasculitis in SAVI: Extension of the Phenotypic Spectrum, Case Report and Review of the Literature. Frontiers in Immunology, 2020, 11, 575219.	4.8	32
39	Apparent Radiological Improvement in an Infant With Labrune Syndrome Treated With Bevacizumab. Pediatric Neurology, 2020, 112, 53-55.	2.1	7
40	Mutations in <i>COPA</i> lead to abnormal trafficking of STING to the Golgi and interferon signaling. Journal of Experimental Medicine, 2020, 217, .	8.5	130
41	Magnetic resonance imaging pattern recognition in childhood bilateral basal ganglia disorders. Brain Communications, 2020, 2, fcaa178.	3.3	17
42	Clinical Reasoning: A 25-year-old woman with recurrent episodes of collapse and loss of consciousness. Neurology, 2020, 94, 994-999.	1.1	2
43	Cardiac valve involvement in <i>ADAR</i> -related type I interferonopathy. Journal of Medical Genetics, 2020, 57, 475-478.	3.2	19
44	Catatonia in a patient with Aicardi-Goutières syndrome efficiently treated with immunoadsorption. Schizophrenia Research, 2020, 222, 484-486.	2.0	6
45	Mendelian disorders of immunity related to an upregulation of type I interferon. , 2020, , 751-772.		2
46	An Indian child with Coats plus syndrome due to mutations in <scp><i>STN1</i></scp> . American Journal of Medical Genetics, Part A, 2020, 182, 2139-2144.	1.2	9
47	Biallelic mutations in NRROS cause an early onset lethal microgliopathy. Acta Neuropathologica, 2020, 139, 947-951.	7.7	17
48	Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatology, The, 2020, 2, e99-e109.	3.9	38
49	Comment on: â€~Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors' by Giannelou et al: mutations in TRNT1 result in a constitutive activation of type I interferon signalling. Annals of the Rheumatic Diseases, 2019, 78, e86-e86.	0.9	12
50	Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice. Journal of Allergy and Clinical Immunology, 2019, 143, 712-725.e5.	2.9	74
51	COPA Syndrome as a Cause of Lupus Nephritis. Kidney International Reports, 2019, 4, 1187-1189.	0.8	19
52	Leukoencephalopathy, Intracranial Calcifications, Cysts, and SNORD118 Mutation (Labrune Syndrome) with Obstructive Hydrocephalus. World Neurosurgery, 2019, 125, 271-272.	1.3	15
53	Bloom syndrome protein restrains innate immune sensing of micronuclei by cGAS. Journal of Experimental Medicine, 2019, 216, 1199-1213.	8.5	75
54	Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in <i>STAT2</i> . Science Immunology, 2019, 4, .	11.9	80

#	Article	IF	CITATIONS
55	Understanding the evolving phenotype of vascular complications in telomere biology disorders. Angiogenesis, 2019, 22, 95-102.	7.2	45
56	DDX58 and Classic Singleton-Merten Syndrome. Journal of Clinical Immunology, 2019, 39, 75-80.	3.8	37
57	Self-Awareness: Nucleic Acid–Driven Inflammation and the Type I Interferonopathies. Annual Review of Immunology, 2019, 37, 247-267.	21.8	111
58	Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Annals of the Rheumatic Diseases, 2019, 78, 431-433.	0.9	53
59	Familial Blau syndrome:First molecularly confirmed report from India. Indian Journal of Ophthalmology, 2019, 67, 165.	1.1	6
60	An open-label trial of JAK 1/2 blockade in progressive <i>IFIH1</i> -associated neuroinflammation. Neurology, 2018, 90, 289-291.	1.1	60
61	Sort Your Self Out!. Cell, 2018, 172, 640-642.	28.9	5
62	Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders. American Journal of Human Genetics, 2018, 102, 175-187.	6.2	204
63	Comprehensive molecular screening strategy of <i><scp>OCLN</scp></i> in bandâ€like calcification with simplified gyration and polymicrogyria. Clinical Genetics, 2018, 93, 228-234.	2.0	9
64	International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. Journal of Clinical Immunology, 2018, 38, 96-128.	3.8	732
65	The 2017 IUIS Phenotypic Classification for Primary Immunodeficiencies. Journal of Clinical Immunology, 2018, 38, 129-143.	3.8	488
66	JAK 1/2 Blockade in MDA5 Gain-of-Function. Journal of Clinical Immunology, 2018, 38, 844-846.	3.8	24
67	Reverse-Transcriptase Inhibitors in the Aicardi–Goutières Syndrome. New England Journal of Medicine, 2018, 379, 2275-2277.	27.0	106
68	A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain, 2018, 141, e80-e80.	7.6	58
69	A Brief Historical Perspective on the Pathological Consequences of Excessive Type I Interferon Exposure In vivo. Journal of Clinical Immunology, 2018, 38, 694-698.	3.8	21
70	Autosomal-dominant early-onset spastic paraparesis with brain calcification due to <i>IFIH1</i> gain-of-function. Human Mutation, 2018, 39, 1076-1080.	2.5	8
71	Mitochondrial double-stranded RNA triggers antiviral signalling in humans. Nature, 2018, 560, 238-242.	27.8	397
72	Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α. Journal of Visualized Experiments, 2018, , .	0.3	8

#	Article	IF	CITATIONS
73	Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. Journal of Experimental Medicine, 2018, 215, 2567-2585.	8.5	146
74	Taking the STING out of inflammation. Nature Reviews Rheumatology, 2018, 14, 508-509.	8.0	6
75	Disease-associated mutations identify a novel region in human STING necessary for the control of type I interferon signaling. Journal of Allergy and Clinical Immunology, 2017, 140, 543-552.e5.	2.9	159
76	Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease. Neuropediatrics, 2017, 48, 166-184.	0.6	62
77	Brief Report: Blockade of TANKâ€Binding Kinase 1/IKKÉ› Inhibits Mutant Stimulator of Interferon Genes (STINC)–Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells. Arthritis and Rheumatology, 2017, 69, 1495-1501.	5.6	22
78	Detection of interferon alpha protein reveals differential levels and cellular sources in disease. Journal of Experimental Medicine, 2017, 214, 1547-1555.	8.5	288
79	MDA5-Associated Neuroinflammation and the Singleton–Merten Syndrome: Two Faces of the Same Type I Interferonopathy Spectrum. Journal of Interferon and Cytokine Research, 2017, 37, 214-219.	1.2	21
80	Polymorphisms in IFIH1: the good and the bad. Nature Immunology, 2017, 18, 708-709.	14.5	7
81	Musculoskeletal Disease in MDA5â€Related Type I Interferonopathy: A Mendelian Mimic of Jaccoud's Arthropathy. Arthritis and Rheumatology, 2017, 69, 2081-2091.	5.6	44
82	Treatment of Leukoencephalopathy With Calcifications and Cysts With Bevacizumab. Pediatric Neurology, 2017, 71, 56-59.	2.1	24
83	Familial and syndromic lupus share the same phenotype as other early-onset forms of lupus. Joint Bone Spine, 2017, 84, 589-593.	1.6	7
84	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. Journal of Clinical Immunology, 2017, 37, 123-132.	3.8	163
85	Modeling of TREX1-Dependent Autoimmune Disease using Human Stem Cells Highlights L1 Accumulation as a Source of Neuroinflammation. Cell Stem Cell, 2017, 21, 319-331.e8.	11.1	254
86	Leukoencephalopathy with calcification and cysts: A cerebral microangiopathy caused by mutations in SNORD118. Journal of the Neurological Sciences, 2017, 372, 443.	0.6	2
87	Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood. Journal of Allergy and Clinical Immunology, 2017, 139, 360-363.e6.	2.9	41
88	Tartrateâ€Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 131-142.	5.6	47
89	Type I interferon-mediated autoinflammation due to DNase II deficiency. Nature Communications, 2017, 8, 2176.	12.8	164
90	JAK inhibition in STING-associated interferonopathy. Annals of the Rheumatic Diseases, 2016, 75, e75-e75.	0.9	22

#	Article	IF	CITATIONS
91	Clinical, radiological and possible pathological overlap of cystic leukoencephalopathy without megalencephaly and Aicardi-Goutières syndrome. European Journal of Paediatric Neurology, 2016, 20, 604-610.	1.6	29
92	Mutations in SNORD118 cause the cerebral microangiopathy leukoencephalopathy with calcifications and cysts. Nature Genetics, 2016, 48, 1185-1192.	21.4	114
93	Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi–GoutiÔres Syndrome and Beyond. Neuropediatrics, 2016, 47, 355-360.	0.6	127
94	Type I interferon–mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. Journal of Experimental Medicine, 2016, 213, 2527-2538.	8.5	359
95	Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. Journal of Experimental Medicine, 2016, 213, 1163-1174.	8.5	224
96	Spondyloenchondrodysplasia Due to Mutations in ACP5: A Comprehensive Survey. Journal of Clinical Immunology, 2016, 36, 220-234.	3.8	71
97	A POT1 mutation implicates defective telomere end fill-in and telomere truncations in Coats plus. Genes and Development, 2016, 30, 812-826.	5.9	77
98	Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome. Neurology, 2016, 86, 28-35.	1.1	59
99	Stimulator of Interferon Genes–Associated Vasculopathy With Onset in Infancy. JAMA Dermatology, 2015, 151, 872.	4.1	108
100	Aicardi–Goutières syndrome and the type I interferonopathies. Nature Reviews Immunology, 2015, 15, 429-440.	22.7	705
101	Early-Onset Aicardi-Goutières Syndrome. Journal of Child Neurology, 2015, 30, 1343-1348.	1.4	33
102	A Specific IFIH1 Gain-of-Function Mutation Causes Singleton-Merten Syndrome. American Journal of Human Genetics, 2015, 96, 275-282.	6.2	188
103	Mosaic structural variation in children with developmental disorders. Human Molecular Genetics, 2015, 24, 2733-2745.	2.9	54
104	Aicardi–Goutières syndrome harbours abundant systemic and brain-reactive autoantibodies. Annals of the Rheumatic Diseases, 2015, 74, 1931-1939.	0.9	35
105	Characterization of human disease phenotypes associated with mutations in <i>TREX1</i> , <i>RNASEH2A</i> , <i>RNASEH2B</i> , <i>RNASEH2C</i> , <i>SAMHD1</i> , <i>ADAR</i> , and <i>IFIH1</i> . American Journal of Medical Genetics, Part A, 2015, 167, 296-312.	1.2	447
106	Update and Mutational Analysis of <i>SLC20A2</i> : A Major Cause of Primary Familial Brain Calcification. Human Mutation, 2015, 36, 489-495.	2.5	80
107	The eukaryotic elongation factor eEF1A1 interacts with SAMHD1. Biochemical Journal, 2015, 466, 69-76.	3.7	14
108	Characterization of <i>samhd1</i> Morphant Zebrafish Recapitulates Features of the Human Type I Interferonopathy Aicardi-Goutières Syndrome. Journal of Immunology, 2015, 194, 2819-2825.	0.8	36

#	Article	IF	CITATIONS
109	Human Disease Phenotypes Associated With Mutations in TREX1. Journal of Clinical Immunology, 2015, 35, 235-243.	3.8	154
110	PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator–dependent autoimmunity. Journal of Allergy and Clinical Immunology, 2015, 135, 1578-1588.e5.	2.9	84
111	Neuromyelitis optica in a child with Aicardi-GoutiÃ^res syndrome. Neurology, 2015, 85, 381-383.	1.1	22
112	Mosaic Tetrasomy 9p: A Mendelian Condition Associated With Pediatric-Onset Overlap Myositis. Pediatrics, 2015, 136, e544-e547.	2.1	10
113	Novel monogenic diseases causing human autoimmunity. Current Opinion in Immunology, 2015, 37, 1-5.	5.5	18
114	cGMP-AMP synthase paves the way to autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12903-12904.	7.1	6
115	Large-scale discovery of novel genetic causes of developmental disorders. Nature, 2015, 519, 223-228.	27.8	998
116	Human intracellular ISG15 prevents interferon- $\hat{l}\pm/\hat{l}^2$ over-amplification and auto-inflammation. Nature, 2015, 517, 89-93.	27.8	432
117	Type I interferonopathies: Mendelian type I interferon up-regulation. Current Opinion in Immunology, 2015, 32, 7-12.	5.5	160
118	ADAR1 Facilitates HIV-1 Replication in Primary CD4+ T Cells. PLoS ONE, 2015, 10, e0143613.	2.5	16
119	Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. Journal of Clinical Investigation, 2014, 124, 5516-5520.	8.2	435
120	STING-Associated Vasculopathy with Onset in Infancy — A New Interferonopathy. New England Journal of Medicine, 2014, 371, 568-571.	27.0	77
121	Leukoencephalopathy with Calcifications and Cysts: A Purely Neurological Disorder Distinct from Coats Plus. Neuropediatrics, 2014, 45, 175-182.	0.6	41
122	Mutations in ADAR1, IFIH1, and RNASEH2B Presenting As Spastic Paraplegia. Neuropediatrics, 2014, 45, 386-391.	0.6	72
123	Basal Ganglia Calcification in a Patient With Beta-Propeller Protein-Associated Neurodegeneration. Pediatric Neurology, 2014, 51, 843-845.	2.1	17
124	Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatric Rheumatology, 2014, 12, 44.	2.1	88
125	PRKDC mutations associated with immunodeficiency, granuloma and aire-dependent autoimmunity. Pediatric Rheumatology, 2014, 12, .	2.1	1
126	A type I interferon signature identifies bilateral striatal necrosis due to mutations in <i>ADAR1</i> . Journal of Medical Genetics, 2014, 51, 76-82.	3.2	118

#	Article	IF	CITATIONS
127	Reply. Arthritis and Rheumatology, 2014, 66, 229-230.	5.6	0
128	Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nature Genetics, 2014, 46, 503-509.	21.4	490
129	Clinical delineation and natural history of the <i>PIK3CA</i> â€related overgrowth spectrum. American Journal of Medical Genetics, Part A, 2014, 164, 1713-1733.	1.2	249
130	Intracranial calcification in childhood: a review of aetiologies and recognizable phenotypes. Developmental Medicine and Child Neurology, 2014, 56, 612-626.	2.1	132
131	The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nature Immunology, 2014, 15, 839-845.	14.5	170
132	Mutations in PIEZO2 Cause Gordon Syndrome, Marden-Walker Syndrome, and Distal Arthrogryposis Type 5. American Journal of Human Genetics, 2014, 94, 734-744.	6.2	171
133	SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood, 2014, 123, 1021-1031.	1.4	205
134	Mendelian Disorders of Immunity Related to an Upregulation of Type I Interferon. , 2014, , 591-602.		0
135	SAMHD1-dependent retroviral control and escape in mice. EMBO Journal, 2013, 32, 2454-2462.	7.8	141
136	Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurology, The, 2013, 12, 1159-1169.	10.2	473
137	Exudative retinopathy, cerebral calcifications, duodenal atresia, preaxial polydactyly, micropenis, microcephaly and short stature: A new syndrome?. American Journal of Medical Genetics, Part A, 2013, 161, 1829-1832.	1.2	2
138	Recognizable phenotypes associated with intracranial calcification. Developmental Medicine and Child Neurology, 2013, 55, 46-57.	2.1	68
139	Striking intrafamilial phenotypic variability in Aicardi–GoutiÔres syndrome associated with the recurrent Asian founder mutation in <i>RNASEH2C</i> . American Journal of Medical Genetics, Part A, 2013, 161, 338-342.	1.2	28
140	Elevation of proinflammatory cytokines in patients with Aicardi-Goutières syndrome. Neurology, 2013, 80, 997-1002.	1.1	23
141	Aicardi–GoutiÔres syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1629-1635.	1.8	69
142	Protein Kinase Cl̂´ Deficiency Causes Mendelian Systemic Lupus Erythematosus With B Cellâ€Defective Apoptosis and Hyperproliferation. Arthritis and Rheumatism, 2013, 65, 2161-2171.	6.7	155
143	Systemic lupus erythematosus due to C1q deficiency with progressive encephalopathy, intracranial calcification and acquired moyamoya cerebral vasculopathy. Lupus, 2013, 22, 639-643.	1.6	29
144	Synonymous Mutations in <i>RNASEH2A</i> Create Cryptic Splice Sites Impairing RNase H2 Enzyme Function in Aicardi-Goutières Syndrome. Human Mutation, 2013, 34, 1066-1070.	2.5	16

#	Article	IF	CITATIONS
145	Therapies in Aicardi–GoutiÔres syndrome. Clinical and Experimental Immunology, 2013, 175, 1-8.	2.6	74
146	Diagnosing fetal alcohol syndrome: new insights from newer genetic technologies. Archives of Disease in Childhood, 2012, 97, 812-817.	1.9	36
147	Intracranial calcification in early infantile Krabbe disease: nothing new under the sun. Developmental Medicine and Child Neurology, 2012, 54, 376-379.	2.1	14
148	SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+T-cells. Retrovirology, 2012, 9, 87.	2.0	302
149	Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. Nature Genetics, 2012, 44, 338-342.	21.4	234
150	Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nature Genetics, 2012, 44, 1243-1248.	21.4	712
151	Autoimmunity. Current Opinion in Immunology, 2012, 24, 649-650.	5.5	1
152	How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. European Journal of Human Genetics, 2012, 20, 381-388.	2.8	142
153	SAMHD1 is a nucleic-acid binding protein that is mislocalized due to aicardi-goutières syndrome-associated mutations. Human Mutation, 2012, 33, 1116-1122.	2.5	121
154	SAMHD1, A Putative Tumour Suppressor, Is Recurrently Mutated in Chronic Lymphocytic Leukaemia, and Is Associated with Poor Risk Features. Blood, 2012, 120, 713-713.	1.4	0
155	Degos Disease. American Journal of Clinical Pathology, 2011, 135, 599-610.	0.7	91
156	Molecular screening of ADAMTSL2 gene in 33 patients reveals the genetic heterogeneity of geleophysic dysplasia. Journal of Medical Genetics, 2011, 48, 417-421.	3.2	45
157	HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature, 2011, 480, 379-382.	27.8	707
158	Sequencing revolution. Developmental Medicine and Child Neurology, 2011, 53, 673-674.	2.1	0
159	Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nature Genetics, 2011, 43, 127-131.	21.4	214
160	Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3. European Journal of Human Genetics, 2011, 19, 18-22.	2.8	50
161	Type I interferonopathies: a novel set of inborn errors of immunity. Annals of the New York Academy of Sciences, 2011, 1238, 91-98.	3.8	337
162	Paediatric stroke: genetic insights into disease mechanisms and treatment targets. Lancet Neurology, The, 2011, 10, 264-274.	10.2	57

#	Article	IF	CITATIONS
163	Infantile neurological Degos disease. European Journal of Paediatric Neurology, 2011, 15, 167-170.	1.6	9
164	Identification and Characterization of an Inborn Error of Metabolism Caused by Dihydrofolate Reductase Deficiency. American Journal of Human Genetics, 2011, 88, 216-225.	6.2	90
165	Phenotypic variation in familial chilblain lupus (FCL) and Aicardi-Goutières syndrome (AGS) associated with TREX1 mutation in 4 family members. Pediatric Rheumatology, 2011, 9, .	2.1	Ο
166	Autosomal dominant inheritance of a heterozygous mutation in <i>SAMHD1</i> causing familial childran lupus. American Journal of Medical Genetics, Part A, 2011, 155, 235-237.	1.2	97
167	Newly recognized recessive syndrome characterized by dysmorphic features, hypogonadotropic hypogonadism, severe microcephaly, and sensorineural hearing loss maps to 3p21.3. American Journal of Medical Genetics, Part A, 2011, 155, 2910-2915.	1.2	2
168	Severe neonatalâ€onset panniculitis in a female infant with Prader–Willi syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 3087-3089.	1.2	0
169	Lupus: How much "complexity―is really (just) genetic heterogeneity?. Arthritis and Rheumatism, 2011, 63, 3661-3664.	6.7	27
170	Cerebral vasculopathy is a common feature in Aicardi–Goutières syndrome associated with <i>SAMHD1</i> mutations. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E232; author reply E233.	7.1	29
171	COL4A1 Mutations Associated with a Characteristic Pattern of Intracranial Calcification. Neuropediatrics, 2011, 42, 227-233.	0.6	38
172	3C syndrome. American Journal of Medical Genetics, Part A, 2010, 152A, 1026-1027.	1.2	5
173	Brown-Vialetto-Van Laere Syndrome, a Ponto-Bulbar Palsy with Deafness, Is Caused by Mutations in C20orf54. American Journal of Human Genetics, 2010, 86, 485-489.	6.2	161
174	Recessive Mutations in the Gene Encoding the Tight Junction Protein Occludin Cause Band-like Calcification with Simplified Gyration and Polymicrogyria. American Journal of Human Genetics, 2010, 87, 354-364.	6.2	123
175	The story of DNase II: A stifled deathâ€wish leads to selfâ€harm. European Journal of Immunology, 2010, 40, 2376-2378.	2.9	4
176	Familial Aicardi–GoutiÔres syndrome due to <i>SAMHD1</i> mutations is associated with chronic arthropathy and contractures. American Journal of Medical Genetics, Part A, 2010, 152A, 938-942.	1.2	73
177	New subtype of familial intracranial calcification in a mother and two children. American Journal of Medical Genetics, Part A, 2010, 152A, 943-946.	1.2	4
178	A de novo p.Asp18Asn mutation in <i>TREX1</i> in a patient with Aicardi–Goutières syndrome. American Journal of Medical Genetics, Part A, 2010, 152A, 2612-2617.	1.2	35
179	Intracerebral large artery disease in Aicardi–GoutiÔres syndrome implicates SAMHD1 in vascular homeostasis. Developmental Medicine and Child Neurology, 2010, 52, 725-732.	2.1	89
180	Treatment of Gastrointestinal Bleeding in a Probable Case of Cerebroretinal Microangiopathy with Calcifications and Cysts. Molecular Syndromology, 2010, 1, 159-162.	0.8	11

#	Article	IF	CITATIONS
181	Chilblains as a Diagnostic Sign of Aicardi-Goutières Syndrome. Neuropediatrics, 2010, 41, 18-23.	0.6	32
182	Expanding the clinical spectrum of SLC29A3 gene defects. European Journal of Medical Genetics, 2010, 53, 309-313.	1.3	38
183	Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Human Molecular Genetics, 2009, 18, R130-R136.	2.9	258
184	Atypical Progeroid Syndrome due to Heterozygous Missense LMNA Mutations. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4971-4983.	3.6	113
185	Aicardi-Goutières Syndrome: Neuroradiologic Findings and Follow-Up. American Journal of Neuroradiology, 2009, 30, 1971-1976.	2.4	72
186	Aicardi–Goutières syndrome presenting with haematemesis in infancy. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 2005-2008.	1.5	2
187	Mutations in MFSD8/CLN7 are a frequent cause of variant-late infantile neuronal ceroid lipofuscinosis. Human Mutation, 2009, 30, E530-E540.	2.5	59
188	Mutations involved in Aicardi-Goutières syndrome implicate SAMHD1 as regulator of the innate immune response. Nature Genetics, 2009, 41, 829-832.	21.4	610
189	Elevated pterins in cerebral spinal fluid– biochemical marker of Aicardi–Goutières syndrome. Developmental Medicine and Child Neurology, 2009, 51, 841-842.	2.1	5
190	Infection-Triggered Familial or Recurrent Cases of Acute Necrotizing Encephalopathy Caused by Mutations in a Component of the Nuclear Pore, RANBP2. American Journal of Human Genetics, 2009, 84, 44-51.	6.2	291
191	Mutation of the Variant α-Tubulin TUBA8 Results in Polymicrogyria with Optic Nerve Hypoplasia. American Journal of Human Genetics, 2009, 85, 737-744.	6.2	151
192	Blue (or purple) toes: Chilblains or chilblain lupus-like lesions are a manifestation of Aicardi–GoutiÔres syndrome and familial chilblain lupus. Journal of the American Academy of Dermatology, 2009, 61, 727-728.	1.2	22
193	Cerebroretinal microangiopathy with calcifications and cysts (CRMCC). American Journal of Medical Genetics, Part A, 2008, 146A, 182-190.	1.2	87
194	A further example of a distinctive autosomal recessive syndrome comprising neonatal diabetes mellitus, intestinal atresias and gall bladder agenesis. American Journal of Medical Genetics, Part A, 2008, 146A, 1713-1717.	1.2	38
195	Two further cases of spondyloenchondrodysplasia (SPENCD) with immune dysregulation. American Journal of Medical Genetics, Part A, 2008, 146A, 2810-2815.	1.2	30
196	Bandâ€like intracranial calcification with simplified gyration and polymicrogyria: A distinct "pseudoâ€TORCH―phenotype. American Journal of Medical Genetics, Part A, 2008, 146A, 3173-3180.	1.2	46
197	Cutaneous histopathological findings of Aicardi–Goutières syndrome, overlap with chilblain lupus. Journal of Cutaneous Pathology, 2008, 35, 774-778.	1.3	47
198	ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-β bioavailability regulation. Nature Genetics, 2008, 40, 1119-1123.	21.4	211

#	Article	IF	CITATIONS
199	tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nature Genetics, 2008, 40, 1113-1118.	21.4	217
200	8p23.1 duplication syndrome; a novel genomic condition with unexpected complexity revealed by array CGH. European Journal of Human Genetics, 2008, 16, 18-27.	2.8	74
201	Aicardiâ€Goutières syndrome: an important Mendelian mimic of congenital infection. Developmental Medicine and Child Neurology, 2008, 50, 410-416.	2.1	125
202	Aicardiâ€Goutières syndrome: description of a late onset case. Developmental Medicine and Child Neurology, 2008, 50, 631-634.	2.1	35
203	Aicardi–GoutiÔres syndrome presenting atypically as a sub-acute leukoencephalopathy. European Journal of Paediatric Neurology, 2008, 12, 408-411.	1.6	27
204	The neonatal form of Aicardi-Goutières syndrome masquerading as congenital infection. Early Human Development, 2008, 84, 783-785.	1.8	16
205	Mutations in the Pericentrin (<i>PCNT</i>) Gene Cause Primordial Dwarfism. Science, 2008, 319, 816-819.	12.6	370
206	Delineation of Late Onset Hypoventilation Associated with Hypothalamic Dysfunction Syndrome. Pediatric Research, 2008, 64, 689-694.	2.3	63
207	Variable Phenotype Including Leigh Syndrome with a 9185T>C Mutation in the <i>MTATP6</i> Gene. Neuropediatrics, 2007, 38, 313-316.	0.6	45
208	The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain, 2007, 130, 843-852.	7.6	501
209	Focal dermal hypoplasia with subependymal heterotopia and hypoplastic corpus callosum. Clinical Dysmorphology, 2007, 16, 59-61.	0.3	2
210	Heterozygous Mutations in TREX1 Cause Familial Chilblain Lupus and Dominant Aicardi-Goutières Syndrome. American Journal of Human Genetics, 2007, 80, 811-815.	6.2	339
211	Clinical and Molecular Phenotype of Aicardi-Goutières Syndrome. American Journal of Human Genetics, 2007, 81, 713-725.	6.2	375
212	Neurological presentation of Griscelli syndrome: Obstructive hydrocephalus without haematological abnormalities or organomegaly. Brain and Development, 2007, 29, 247-250.	1.1	18
213	Reduced penetrance alleles for Huntington's disease: a multi-centre direct observational study. Journal of Medical Genetics, 2006, 44, e68-e68.	3.2	67
214	Clinical phenotype associated with homozygosity forÂaÂHOXD13 7-residue polyalanine tract expansion. European Journal of Medical Genetics, 2006, 49, 396-401.	1.3	19
215	Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutières syndrome and mimic congenital viral brain infection. Nature Genetics, 2006, 38, 910-916.	21.4	592
216	Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nature Genetics, 2006, 38, 917-920.	21.4	752

#	Article	IF	CITATIONS
217	A newly recognized, likely autosomal recessive syndrome comprising agammaglobulinemia, microcephaly, craniosynostosis, severe dermatitis, and other features. American Journal of Medical Genetics, Part A, 2006, 140A, 1131-1135.	1.2	1
218	Sedaghatian spondylometaphyseal dysplasia with pachygyria and absence of the corpus callosum. American Journal of Medical Genetics, Part A, 2006, 140A, 1854-1858.	1.2	5
219	Elevated Interferon-Alpha in Fetal Blood in the Prenatal Diagnosis of Aicardi-Goutières Syndrome. Fetal Diagnosis and Therapy, 2006, 21, 153-155.	1.4	11
220	Severe childhood SMA and axonal CMT due to anticodon binding domain mutations in the GARS gene. Neurology, 2006, 67, 1710-1712.	1.1	72
221	Mental retardation, keratoconus, febrile seizures and sinoatrial block: a previously undescribed autosomal recessive disorder. Clinical Genetics, 2005, 67, 448-449.	2.0	10
222	Brown–Vialetto–Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease. Brain and Development, 2005, 27, 443-446.	1.1	45
223	Natural history of cardiac involvement in geleophysic dysplasia. , 2005, 132A, 320-323.		18
224	Congenital palmar polyonychia with postaxial limb defects may be the same as the ulnar-mammary syndrome. American Journal of Medical Genetics, Part A, 2005, 137A, 233-233.	1.2	0
225	Chromosome 1q42 deletion and agenesis of the corpus callosum. American Journal of Medical Genetics, Part A, 2005, 138A, 68-69.	1.2	18
226	A second locus for Aicardi-Goutieres syndrome at chromosome 13q14-21. Journal of Medical Genetics, 2005, 43, 444-450.	3.2	33
227	Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. Journal of Medical Genetics, 2005, 43, 451-456.	3.2	62
228	Genetic syndromes mimic congenital infections. Journal of Pediatrics, 2005, 146, 701-705.	1.8	54
229	Clinical and Mutational Spectrum of Mowat–Wilson Syndrome. European Journal of Medical Genetics, 2005, 48, 97-111.	1.3	121
230	Coats' Plus: A Progressive Familial Syndrome of Bilateral Coats' Disease, Characteristic Cerebral Calcification, Leukoencephalopathy, Slow Pre- and Post-Natal Linear Growth and Defects of Bone Marrow and Integument. Neuropediatrics, 2004, 35, 10-19.	0.6	77
231	Congenital glaucoma and brain stem atrophy as features of Aicardi-Goutières syndrome. , 2004, 129A, 303-307.		30
232	Mutations in the Transmembrane Natriuretic Peptide Receptor NPR-B Impair Skeletal Growth and Cause Acromesomelic Dysplasia, Type Maroteaux. American Journal of Human Genetics, 2004, 75, 27-34.	6.2	325
233	Identification of Microcephalin, a Protein Implicated in Determining the Size of the Human Brain. American Journal of Human Genetics, 2002, 71, 136-142.	6.2	499
234	The genetics of Aicardi-Goutières syndrome. European Journal of Paediatric Neurology, 2002, 6, A33-A35.	1.6	5

#	Article	IF	CITATIONS
235	ASPM is a major determinant of cerebral cortical size. Nature Genetics, 2002, 32, 316-320.	21.4	538
236	Aicardi-Goutières Syndrome Displays Genetic Heterogeneity with One Locus (AGS1) on Chromosome 3p21. American Journal of Human Genetics, 2000, 67, 213-221.	6.2	77
237	A Fifth Locus for Primary Autosomal Recessive Microcephaly Maps to Chromosome 1q31. American Journal of Human Genetics, 2000, 67, 1578-1580.	6.2	101
238	The Molecular Basis of GROD-Storing Neuronal Ceroid Lipofuscinoses in Scotland. Molecular Genetics and Metabolism, 1999, 66, 245-247.	1.1	10
239	Mutations in the palmitoyl-protein thioesterase gene (PPT; CLN1) causing juvenile neuronal ceroid lipofuscinosis with granular osmiophilic deposits [published erratum appears in Hum Mol Genet 1998 Apr;7(4):765]. Human Molecular Genetics, 1998, 7, 291-297.	2.9	122
240	Spondylocostal dysostosis associated with a 46,XX,+15,dic(6;15)(q25;qll.2) translocation. Clinical Dysmorphology, 1997, 6, 347-350.	0.3	16
241	Maternal serum alpha-fetoprotein levels in congenital nephrosis. , 1997, 17, 1089-1089.		5
242	A child with severe juvenile dermatomyositis treated with ruxolitinib. Journal of Financial Econometrics, 0, , .	1.5	0